{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:53:55Z","timestamp":1792536835468,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2016.10.090","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T09:31:22Z","timestamp":1488533482000},"page":"7315-7327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Report from the World Health Organization\u2019s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8\u201310th June 2016"],"prefix":"10.1016","volume":"37","author":[{"given":"Birgitte K.","family":"Giersing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-970X","authenticated-orcid":false,"given":"Samantha","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasee","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.090_b0005","unstructured":"Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. <http:\/\/www.who.int\/immunization_standards\/vaccine_quality\/TRS_978_61st_report_Annex_6_PQ_vaccine_procedure.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0010","unstructured":"Tackling drug resistant infections globally: Final report and recommendation. <http:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf>."},{"issue":"3","key":"10.1016\/j.vaccine.2016.10.090_b0015","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00428-16","article-title":"How can vaccines contribute to solving the antimicrobial resistance problem?","volume":"7","author":"Lipsitch","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2016.10.090_b0020","unstructured":"WHO Vaccine Pipeline tracker. <http:\/\/who.int\/immunization\/research\/vaccine_pipeline_tracker_spreadsheet\/en\/>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0025","doi-asserted-by":"crossref","unstructured":"Giersing Birgitte K, Modjarrad Kayvon, Moorthy Vasee S, WHO Product Development for Vaccines Advisory Committee (PDVAC) Pipeline Analyses for 25 Pathogens, vol. 34(26). p. 2863\u20133006.","DOI":"10.1016\/j.vaccine.2016.04.041"},{"key":"10.1016\/j.vaccine.2016.10.090_b0030","unstructured":"Weekly epidemiological record, 11 Dec 2015, No. 50, 2015, 90, 681\u2013700. <http:\/\/www.who.int\/wer\/2015\/wer9050.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0035","unstructured":"Weekly epidemiological record 27 May 2016, No 21, 2016, 91, 265\u2013284. <http:\/\/www.who.int\/wer\/2016\/wer9121.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0040","doi-asserted-by":"crossref","unstructured":"O'Brien K, Binka F, Marsh K, Abramson JS. Mind the gap: jumping from vaccine licensure to routine use 2016;387(10031):1887\u20139.","DOI":"10.1016\/S0140-6736(16)30394-4"},{"key":"10.1016\/j.vaccine.2016.10.090_b0045","unstructured":"Global Vaccine Action Plan (GVAP). <http:\/\/www.who.int\/immunization\/global_vaccine_action_plan\/DoV_GVAP_2012_2020\/en\/>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0050","unstructured":"SAGE GVAP Assessment Report 2015. <http:\/\/www.who.int\/immunization\/global_vaccine_action_plan\/SAGE_GVAP_Assessment_Report_2015_EN.pdf>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0055","unstructured":"Global TB Report 2015. <http:\/\/apps.who.int\/iris\/bitstream\/10665\/191102\/1\/9789241565059_eng.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0060","unstructured":"The End TB Strategy. <http:\/\/www.who.int\/tb\/End_TB_brochure.pdf>."},{"issue":"43","key":"10.1016\/j.vaccine.2016.10.090_b0065","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"Knight","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"10.1016\/j.vaccine.2016.10.090_b0070","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.vaccine.2016.02.079","article-title":"Status of vaccine research and development of vaccines for tuberculosis","volume":"34","author":"Evans","year":"2016","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2016.10.090_b0075","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.090_b0080","unstructured":"<https:\/\/www.niaid.nih.gov\/news-events\/first-new-hiv-vaccine-efficacy-study-seven-years-has-begun>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0085","unstructured":"WHO World Malaria Report 2015: <http:\/\/apps.who.int\/iris\/bitstream\/10665\/200018\/1\/9789241565158_eng.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0090","doi-asserted-by":"crossref","unstructured":"Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7\u20139th Sep 2015. Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS et al. Vaccine, 2016 Jun 3;34(26):2865\u20139.","DOI":"10.1016\/j.vaccine.2016.02.078"},{"key":"10.1016\/j.vaccine.2016.10.090_b0095","unstructured":"Malaria vaccine roadmap: <http:\/\/www.who.int\/immunization\/topics\/malaria\/vaccine_roadmap\/TRM_update_nov13.pdf?ua=1>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0100","unstructured":"WHO global consultation on universal influenza vaccines, August 2016. <http:\/\/www.who.int\/immunization\/research\/meetings_workshops\/8th_influenza_vaccine_chicago2016\/en\/>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0105","unstructured":"The Global Burden of Norovirus & Prospects for Vaccine Development. <http:\/\/collections.plos.org\/norovirus>."},{"issue":"4","key":"10.1016\/j.vaccine.2016.10.090_b0110","doi-asserted-by":"crossref","first-page":"e1001999","DOI":"10.1371\/journal.pmed.1001999","article-title":"The vast and varied global burden of norovirus: prospects for prevention and control","volume":"13","author":"Lopman","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2016.10.090_b0115","unstructured":"https:\/\/www.takeda.com\/news\/2016\/20160620_7467.html."},{"issue":"62 Suppl 2","key":"10.1016\/j.vaccine.2016.10.090_b0120","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/cid\/civ1013","article-title":"Global, regional, and national estimates of rotavirus mortality in children <5 Years of Age, 2000\u20132013","volume":"1","author":"Tate","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.090_b0125","unstructured":"WHO guidance document for the quality, safety and efficacy of oral live attenuated rotavirus vaccines. <http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/rotavirus\/Annex%203%20rotavirus%20vaccines.pdf?ua=1>."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.10.090_b0130","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1093\/cid\/cis319","article-title":"Current status of Clostridium difficile infection epidemiology","volume":"55","author":"Lessa","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2016.10.090_b0135","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.vaccine.2016.03.028","article-title":"Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized Phase 2 clinical trial","volume":"34","author":"de Bruyn","year":"2016","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2016.10.090_b0140","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.vaccine.2016.03.010","article-title":"A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults","volume":"34","author":"Sheldon","year":"2016","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2016.10.090_b0145","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.vaccine.2016.03.098","article-title":"Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers","volume":"34","author":"B\u00e9zay","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.090_b0150","unstructured":"http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx."},{"key":"10.1016\/j.vaccine.2016.10.090_b0155","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.090_b0160","unstructured":"Edited by M. Nesin, J. Read, M. Koso-Thomas, M. Brewinski Isaacs and A. Sobanjo-ter Meulen Advancing Maternal Immunization Programs through Research in Low and Medium Income Countries Volume 33, Issue 47, Pages 6371\u20136502."},{"issue":"9725","key":"10.1016\/j.vaccine.2016.10.090_b0165","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.090_b0170","unstructured":"http:\/\/www.uu.nl\/en\/news\/first-consortium-of-local-manufacturers-to-make-affordable-biosimilars-available-for-low-income."},{"key":"10.1016\/j.vaccine.2016.10.090_b0175","unstructured":"Kobayashia Miwako, Schrag Stephanie J, Vekemans Johan, Moorthy Vasee S. WHO consultation on Group B Streptococcus vaccine development: report from a meeting held on 27\u201328 April 2016, Vekemans (in preparation)."},{"key":"10.1016\/j.vaccine.2016.10.090_b0180","unstructured":"Global Alignment of Immunization Safety Assessment in Pregnancy: <https:\/\/brightoncollaboration.org\/public\/what-we-do\/Projects\/Gaia.html>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0185","unstructured":"TB Vaccine Research & Development: A Business Case for Investment. <http:\/\/www.aeras.org\/img\/uploads\/attachments\/120\/tb_vaccine_rd_business_case_2014_2.pdf>."},{"key":"10.1016\/j.vaccine.2016.10.090_b0190","unstructured":"Global Action Plan on Antimicrobial Resistance: <http:\/\/apps.who.int\/iris\/bitstream\/10665\/193736\/1\/9789241509763_eng.pdf?ua=1>."},{"issue":"3","key":"10.1016\/j.vaccine.2016.10.090_b0195","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","author":"Pendleton","year":"2013","journal-title":"Expert Rev Anti-infective Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.090_b0200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3201\/eid2202.151358","article-title":"Invasive group A streptococcus infection among children, Rural Kenya","volume":"22","author":"Seale","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2016.10.090_b0205","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4161\/hv.21872","article-title":"Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors","volume":"8","author":"Anderson","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2016.10.090_b0210","unstructured":"Global Health Sector Strategy on Sexually Transmitted Infections <http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA69\/A69_33-en.pdf?ua=1>."},{"issue":"26","key":"10.1016\/j.vaccine.2016.10.090_b0215","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.10.090_b0220","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2016.10.090_b0225","doi-asserted-by":"crossref","first-page":"e0140765","DOI":"10.1371\/journal.pone.0140765","article-title":"Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.10.090_b0230","unstructured":"http:\/\/www.genocea.com\/platform-pipeline\/pipeline\/gen003-for-genital-herpes\/."},{"issue":"12","key":"10.1016\/j.vaccine.2016.10.090_b0235","doi-asserted-by":"crossref","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2016.10.090_b0240","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2307\/2135243","article-title":"The pill, chlamydia and PID","volume":"17","author":"Cates","year":"1985","journal-title":"Fam Plann Perspect"},{"issue":"4","key":"10.1016\/j.vaccine.2016.10.090_b0245","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","article-title":"Hand, foot, and mouth disease in China, 2008\u201312: an epidemiological study","volume":"14","author":"Xing","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2016.10.090_b0250","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2016.10.090_b0255","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.10.090_b0260","unstructured":"http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/07-06-2016-RRA-Enterovirus%2071-Spain.pdf."},{"key":"10.1016\/j.vaccine.2016.10.090_b0265","unstructured":"WHO R&D Roadmap: <http:\/\/www.who.int\/csr\/research-and-development\/WHO-R_D-Final10.pdf?ua=1>."},{"issue":"7","key":"10.1016\/j.vaccine.2016.10.090_b0270","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nm.4131","article-title":"A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation","volume":"22","author":"Modjarrad","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2016.10.090_b0275","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.coviro.2016.03.008","article-title":"On a path to accelerate access to Ebola vaccines: the WHO's research and development efforts during the 2014\u20132016 Ebola epidemic in West Africa","volume":"17","author":"Henao-Restrepo","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2016.10.090_b0280","unstructured":"http:\/\/www.who.int\/immunization\/research\/development\/zika\/en\/."},{"key":"10.1016\/j.vaccine.2016.10.090_b9000","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1016\/j.vaccine.2016.10.034","article-title":"Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency","volume":"37","author":"Vannice","year":"2019","journal-title":"Vaccine"},{"issue":"9730","key":"10.1016\/j.vaccine.2016.10.090_b0285","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0140-6736(10)60549-1","article-title":"Global, regional, and national causes of child mortality in 2008: a systematic analysis","volume":"375","author":"Black","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.10.090_b0290","unstructured":"http:\/\/www.who.int\/gho\/immunization\/en\/."},{"key":"10.1016\/j.vaccine.2016.10.090_b0295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijid.2013.12.010","article-title":"Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries","volume":"22","author":"Lanzieri","year":"2014","journal-title":"Int J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:50:32Z","timestamp":1759402232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":60,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X16312051"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.090","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report from the World Health Organization\u2019s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8\u201310th June 2016","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}